Wynnis Tom, MD
Pediatric Dermatology · San Diego, CANPI 1922215045
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,750 of the $4,462 with a category attached, or 84.0%. Novartis accounts for 84.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $3,824 and has fallen 99.5% since, to $19 in 2025.
Across 35 payments — averaging $127.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4K
- Pfizer$275
- AbbVie$101
- Sanofi$82
- Pierre Fabre Pharmaceuticals, Inc.$77
- Arcutis Biotherapeutics, Inc.$40
- plus $138 from 6 others
Across 254 payments — averaging $2115.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$260K
- Eli Lilly$91K
- AbbVie$62K
- Pfizer$61K
- Incyte Corporation$41K
- Janssen Research & Development, LLC$20K
- plus $2K from 1 others
What the payments were for
- Speaking & faculty fees$3,75084%
- Food & beverage$71216%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 2 | $3,750 |
| Pfizer | 13 | $275 |
| AbbVie | 5 | $101 |
| Sanofi | 3 | $82 |
| Pierre Fabre Pharmaceuticals, Inc. | 4 | $77 |
| Arcutis Biotherapeutics, Inc. | 2 | $40 |
| LEO Pharma Inc. | 1 | $29 |
| VYNE Pharmaceuticals Inc. | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Dermavant Sciences, Inc. | 1 | $22 |
| Lumenis, Inc | 1 | $11 |
How this compares
$4,462 in reported general payments places this provider in the 65th percentile of 36 pediatric dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 42 | $222,061 |
| SantylCollagenase Clostridium Hist. | 16 | $4,730 |
| Tacrolimus | 15 | $3,001 |
| Ketoconazole | 87 | $1,231 |
| Clindamycin Phosphate | 33 | $806 |
| Triamcinolone Acetonide | 50 | $693 |
| Mometasone Furoate | 19 | $573 |
| Metronidazole | 13 | $500 |
| Hydroxyzine Hcl | 11 | $172 |
| Hydrocortisone | 27 | $78 |
Paid to pharmacies, not to this prescriber.
Other pediatric dermatology in San Diego
- Lawrence EichenfieldSan Diego$2.8M
- Dawn EichenfieldSan Diego$252K
- Sheila FriedlanderSan Diego$7K
- Bari CunninghamSan Diego$3K
- Allison HanSan Diego$1K
- Jessica SpragueSan Diego$916
- Catalina MatizSan Diego$672
- David SchairerSan Diego$630
- Susan BoikoSan Diego$527
- Magdalene DohilSan Diego$444
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.